metformin has been researched along with Myositis Ossificans in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Myositis Ossificans: A disease characterized by bony deposits or the ossification of muscle tissue.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, H | 1 |
| Ying, Y | 1 |
| Wang, YY | 1 |
| Wang, G | 1 |
| Jiang, SS | 1 |
| Huang, D | 1 |
| Luo, L | 1 |
| Chen, YG | 1 |
| Gerstenfeld, LC | 1 |
| Luo, Z | 1 |
1 other study available for metformin and Myositis Ossificans
| Article | Year |
|---|---|
AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation.
Topics: Activin Receptors, Type I; AMP-Activated Protein Kinase Kinases; Cell Differentiation; Fibroblasts; | 2017 |